Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 150Lung Neoplasms 58Pancreatic Neoplasms 34Neoplasms 20Neoplasm Metastasis 15Breast Neoplasms 15Adenocarcinoma of Lung 15Brain Neoplasms 14Adenocarcinoma, Bronchiolo-Alveolar 13Glioblastoma 12Non-Squamous Non-Small Cell Lung Cancer 11Head and Neck Neoplasms 11Gliosarcoma 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Hepatocellular 10Colorectal Neoplasms 8Carcinoma, Renal Cell 8Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Gallbladder Neoplasms 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma 5Rectal Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Liver Neoplasms 4Kidney Neoplasms 4Fallopian Tube Neoplasms 4

Interventions

Radiotherapy 2TP protocol 1Paclitaxel 1Erlotinib Hydrochloride 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Recurrence, Local × Erlotinib Hydrochloride × Clear all
NCT00095225 2008-01-29

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

Genentech, Inc.

Phase 2 Completed
122 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Recurrence, Local, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡